Cargando…

Sub-phenotyping of juvenile dermatomyositis: can it assist clinical decisions?

Detalles Bibliográficos
Autores principales:	Yasin, Shireena A, Arnold, Katie, Sag, Erdal, Tansley, Sarah, Moraitis, Elena, Jacques, Thomas S, Holton, Janice L, Owens, Catherine, McHugh, Neil, Pilkington, Clarissa, Wedderburn, Lucy R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184136/ http://dx.doi.org/10.1186/1546-0096-12-S1-O18

Ejemplares similares

Tubuloreticular inclusions in juvenile dermatomyositis: a diagnostically useful marker?
por: Yasin, Shireena A, et al.
Publicado: (2014)

Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study
por: Tansley, Sarah L, et al.
Publicado: (2014)

How do tissue infiltrating B cells and plasma cells correlate with other inflammatory features in muscle tissue from patients with JDM?
por: Sag, Erdal, et al.
Publicado: (2014)

PReS-FINAL-2130: Antibodies to MDA5 correlate with a distinct phenotype in children with juvenile dermatomyositis, including higher risk of lung involvement and ulcerative skin disease
por: Moraitis, E, et al.
Publicado: (2013)

Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?
por: Tansley, Sarah L, et al.
Publicado: (2013)

Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset
por: Tansley, Sarah L., et al.
Publicado: (2014)

Expression of myxovirus‐resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis
por: Soponkanaporn, S., et al.
Publicado: (2018)

Clinically inactive disease in juvenile dermatomyositis – a proposed revision to the printo criteria
por: Almeida, Beverley, et al.
Publicado: (2014)

OA29 Blotting-based assays under-detected TIF1-gamma and NXP2 autoantibodies compared to immunoprecipitation in Juvenile Dermatomyositis cohorts
por: Nguyen, Huong D, et al.
Publicado: (2022)

Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling
por: Deakin, Claire T., et al.
Publicado: (2018)

PReS-FINAL-2130-A: Effectiveness of intravenous cyclophosphamide in severe or refractory juvenile dermatomyositis - a national cohort study UK and Ireland
por: Moraitis, E, et al.
Publicado: (2013)

Comparison of the utility and validity of three scoring tools to detect skin disease in patients with juvenile dermatomyositis
por: Campanilho-Marques, Raquel, et al.
Publicado: (2014)

Identification and prediction of novel classes of long-term disease trajectories for patients with juvenile dermatomyositis using growth mixture models
por: Deakin, Claire T, et al.
Publicado: (2020)

Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features
por: Yasin, S. A., et al.
Publicado: (2019)

8.4 Novel autoantibodies targeting a p140 protein are a major autoantigen system in juvenile dermatomyositis and a marker of calcinosis
por: Gunawardena, H, et al.
Publicado: (2008)

Proposal for the development of an international minimal data collection for juvenile dermatomyositis (JDM)
por: McCann, Liza J, et al.
Publicado: (2011)

Effective induction therapy for anti-SRP associated myositis in childhood: A small case series and review of the literature
por: Binns, E. L., et al.
Publicado: (2017)

Developing a provisional, international Minimal Dataset for Juvenile Dermatomyositis: for use in clinical practice to inform research
por: McCann, Liza J, et al.
Publicado: (2014)

PReS-FINAL-1020: Dysregulation of the peripheral blood D cell compartment is associated with disease activity in juvenile dermatomyositis
por: Piper, C, et al.
Publicado: (2013)

Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
por: Campanilho-Marques, Raquel, et al.
Publicado: (2020)

A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies
por: Martin, Neil, et al.
Publicado: (2011)

Juvenile Dermatomyositis—Clinical Phenotypes
por: Li, Danyang, et al.
Publicado: (2019)

Effectiveness of anti-TNF-α agents in the treatment of refractory juvenile dermatomyositis
por: Boulter, EL, et al.
Publicado: (2011)

Regulatory B cell Il-10 production is diminished in juvenile dermatomyositis
por: Piper, Christopher, et al.
Publicado: (2014)

CD4(+)FOXP3(+) regulatory T cells are abundantly present in inflamed muscle of patients with juvenile dermatomyositis
por: Vercoulen, Yvonne, et al.
Publicado: (2011)

Comparison of Children With Onset of Juvenile Dermatomyositis Symptoms Before or After Their Fifth Birthday in a UK and Ireland Juvenile Dermatomyositis Cohort Study
por: Martin, N, et al.
Publicado: (2012)

Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use
por: McCann, Liza J., et al.
Publicado: (2015)

Anti–Cytosolic 5′‐Nucleotidase 1A Autoantibodies Are Absent in Juvenile Dermatomyositis
por: Rietveld, Anke, et al.
Publicado: (2021)

Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease
por: Varsani, Hemlata, et al.
Publicado: (2015)

Myeloid cells which secrete S100 proteins in juvenile dermatomyositis may contribute to disease activity
por: Varsani, H, et al.
Publicado: (2008)

Toll-like receptor 2 polymorphism in juvenile dermatomyositis
por: Mathiesen, P, et al.
Publicado: (2011)

Consensus-based recommendations for the management of juvenile dermatomyositis
por: Enders, Felicitas Bellutti, et al.
Publicado: (2017)

Being on the juvenile dermatomyositis rollercoaster: a qualitative study
por: Livermore, Polly, et al.
Publicado: (2019)

Maternal microchimerism in muscle biopsies from children with juvenile dermatomyositis
por: Ye, Yi, et al.
Publicado: (2012)

Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis
por: Gunawardena, H, et al.
Publicado: (2009)

Mapping the current psychology provision for children and young people with juvenile dermatomyositis
por: Livermore, Polly, et al.
Publicado: (2021)

SHARE – workpackage 5: evidence based recommendations for diagnosis and treatment of juvenile dermatomyositis
por: Enders, Felicitas Bellutti, et al.
Publicado: (2014)

Muscle Biopsy Findings in Combination With Myositis‐Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis
por: Deakin, Claire T., et al.
Publicado: (2016)

PReS-FINAL-2193: Assessment of construct validity of new measures of global disease activity, physical function and quality of life in children with juvenile dermatomyositis
por: Ferrari, C, et al.
Publicado: (2013)

Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools
por: Wienke, Judith, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gi1012r3m0nj8kkjtoknsf41vq